The 2nd Oxford Myeloma Workshop was a two-day event (1-2 August 2019) run by Oxford University Hospitals which focused on the current translational research priorities in myeloma. Patient Advocacy and Policy Research Officer, Dr Amy Capper was there to learn about the latest developments. Here are some of her highlights from the programme: Opening the…
DetailsThe UK Myeloma Forum (UKMF) is a collaborative organisation of healthcare professionals and scientists which aims to improve the treatment of patients with myeloma. The annual UKMF Scientific Workshop is an all-day event where leading experts share the latest biomedical research aiming to improve understanding of myeloma and develop new strategies to improve patient outcomes. This year’s…
Details
OPTIMISING CURRENT TREATMENTS The number of drugs available as myeloma treatment has grown significantly over the last two decades with discovery and approval of immunomodulatory drugs (thalidomide, lenalidomide (Revlimid®) and pomalidomide (Imnovid®)), proteasome inhibitors (bortezomib (Velcade®), cafilzomib (Kyprolis®) and ixazomib (Ninlaro®)), histone deacetylase inhibitors (panobinostat) and monoclonal antibody drugs (daratumumab (Darzalex®) and elotuzumab (Empliciti®)). However,…
Details
Speaker: Prof Angela Dispenzieri, Mayo Clinic, USA
Details
Speaker: Dr Matthew Jenner, University Hospital Southampton NHS Foundation Trust
Details
Speaker: Dr Andrew Chantry, Sheffield Teaching Hospitals NHS Foundation Trust
Details
Speaker: Prof Gordon Cook, Section of Experimental Haematology, University of Leeds
Details
Speaker: Mr Sean Molloy, Royal National Orthopaedic Hospital, London
Details
Speaker: Prof Heinz Ludwig, Wilhelminenhospital, Vienna. Austria
Details
Charity No: SC 026116
Myeloma UK
22 Logie Mill
Beaverbank Business Park
Edinburgh
EH7 4HG